Home › Funds › Squadron Capital Management LLC › AVBP
Squadron Capital Management LLC position in AVBP
ARRIVENT BIOPHARMA INC COM · Health Care
Squadron Capital Management LLC reported holding 183,000 shares of AVBP (ARRIVENT BIOPHARMA INC COM) in its Q2 2026 13F filing — a position valued at US$6.4M, representing 2.49% of its reported portfolio and ranking #10 among its reported holdings. Squadron Capital Management LLC has disclosed AVBP holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Squadron Capital Management LLC's AVBP position evolved
Squadron Capital Management LLC first disclosed a stake in AVBP in Q4 2025 at 338,000 shares (US$6.8M). Across 3 filings, Squadron Capital Management LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 183,000 shares valued at US$6.4M — an increase of 73,000 shares quarter over quarter.. Notable position changes include a 67% trim in Q1 2026 (shares rose 51% over the following quarter), a 66% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 338.00K | $6.80M | New |
| Q1 2026 | 110.00K | $2.54M | Reduce |
| Q2 2026 | 183.00K | $6.36M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC COM) is a Health Care company. 60 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$156.9M), INFINITUM ASSET MANAGEMENT, LLC (US$154.2M), Hillhouse Capital (HHLR Advisors) (US$136.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- MONTANOVA CAPITAL, LLC 4.52M sh · $156.87M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.44M sh · $154.19M · Q2 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $136.50M · Q2 2026
- ORBIMED ADVISORS LLC 3.03M sh · $105.17M · Q2 2026
- Octagon Capital Advisors LP 1.97M sh · $68.47M · Q2 2026
- Sofinnova Investments, Inc. 1.70M sh · $58.95M · Q2 2026
- Vivo Capital, LLC 1.68M sh · $58.44M · Q2 2026
- Novo Holdings A/S 1.50M sh · $52.11M · Q2 2026
- General Catalyst Group Management, LLC 1.49M sh · $51.93M · Q2 2026
- Logos Global Management LP 1.00M sh · $34.74M · Q2 2026
- HSG Holding Ltd 663.31K sh · $23.04M · Q2 2026
- Foresite Capital Management VI LLC 301.34K sh · $10.47M · Q2 2026
More on Squadron Capital Management LLC
FAQ
How long has Squadron Capital Management LLC held AVBP?
Squadron Capital Management LLC has disclosed AVBP holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Squadron Capital Management LLC's current position in AVBP?
As of Q2 2026, Squadron Capital Management LLC holds 183.00K shares of AVBP (ARRIVENT BIOPHARMA INC COM), valued at $6.36M, representing 2.49% of its reported portfolio and ranking #10.
Has Squadron Capital Management LLC been buying or selling AVBP?
In the latest 13F filing (Q2 2026), Squadron Capital Management LLC increased its position in AVBP.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.